For the quantitative detection of the BCR-ABL p190 e1a2 fusion transcript by real-time PCR in bone marrow or peripheral blood samples of patients who have been diagnosed with Acute Lymphoblastic Leukaemia (ALL) or Chronic Myeloid Leukemia (CML). This test can be used to monitor Minimal Residual Disease (MRD) in patients undergoing therapy